Short Report: Evaluation of leishmanin skin test in Indian visceral leishmaniasis

American Journal of Tropical Medicine and Hygiene

Volumn 80, Issue 4, 2009, Pages 566-567

  Gidwani, Kamlesh ^a   Rai, Madhukar ^a   Chakravarty, Jaya ^a   Boelaert, Marleen ^b   Sundar, Shyam ^a  

^a BANARAS HINDU UNIVERSITY   (India)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDEMIC DISEASE; HUMAN; LEISHMANIA DONOVANI; LEISHMANIA MAJOR; LEISHMANIN SKIN TEST; SENSITIVITY AND SPECIFICITY; VISCERAL LEISHMANIASIS; EVALUATION; IMMUNOLOGY; INDIA; SKIN TEST; TIME;

LEISHMANIA MAJOR;

ANTIPROTOZOAL AGENT; DIAGNOSTIC AGENT; LEISHMANIN; PARASITE ANTIGEN;

ANTIGENS, PROTOZOAN; ANTIPROTOZOAL AGENTS; HUMANS; INDIA; LEISHMANIASIS, VISCERAL; SKIN TESTS; TIME FACTORS;

EID: 65349177693     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2009.80.566     Document Type: Article

References (15)

1. Carvalho EM, Bacellar O, Barral A, Badaro R, Johnson WD Jr, 1989. Antigen-specific immunosuppression in visceral leishmaniasis is cell mediated. J Clin Invest 83:860-864.
2. Khalil EAG, Ayed NB, Musa AM, Ibrahim ME, Mukhtar MM, Zijlstra EE, Elhassan IM, Smith PG, Kieny PM, Ghalib HW, Zicker F, Modabber F, Elhassan AM, 2005. Dichotomy of protective cellular immune responses to human visceral leishmaniasis. Clin Exp Immunol 140:349-353.
3. Desjeux P, 1992. Human leishmaniasis: epidemiology and public health aspects. World Health Stat Q 45:267-275.
4. Sacks DL, Lai SL, Shrivastava SN, Blackwell JM, Neva FA, 1987. An analysis of T cell responsiveness in Indian Kala-azar. J Immunol 138: 908-913.
5. Zijlstra EE, El-Hassan AM, Ismail A, Ghalib HW, 1994. Endemic Kalaazar in eastern Sudan: a longitudinal study of the incidence of clinical and subclinical infection and post kala-azar dermal leishmaniasis. Am J Trop Med Hyg 51:826-836.
6. Antunes CM, Mayrink W, Magalhaes PA, Costa CA, Melo MN, Dias M, Michalick MS, Williams P, Lima AO, Vieira JB, 1986. Controlled field trials of a vaccine against New World cutaneous leishmaniasis. Int J Epidemiol 15:572-580.
7. Khalil EA, El Hassan AM, Zijlstra EE, Mukhtar MM, Ghalib HW, Musa B, Ibrahim ME, Kamil AA, Elsheikh M, Babiker A, Modabber F, 2000. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomized, double-blind, BCG-controlled trial in Sudan. Lancet 356: 1565-1569.
8. Momeni AZ, Jalayer T, Emamjomeh M, Khamesipour A, Zicker F, Labaf-Ghasemi R, 1999. A randomized double-blind, controlled trial of killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran. Vaccine 17:466-472.
9. Zhou XH, Obuchowski NA, McClish DK, 2002. Statistical Methods in Diagnostic Medicine, New York: Wiley & Sons.
10. Sokal JE, 1975. Editorial: Measurement of delayed skin-test responses. N Engl J Med 293:501-502.
11. Manson-Bahr PEC, 1961. Immunity in kala-azar. Trans R Soc Trop Med Hyg 55:550-555.
12. el Safi S, Hamid N, Ahmad-Haleem OA, Hammad A, Kareem HG, Boelaert M, 2004. Infection rates with Leishmania donovani and Mycobacterium tuberculosis in a village in eastern Sudan. Trop Med Int Health 9:1305-1311.
13. Bern C, Amann J, Haque R, Chowdhury AM, Kurkjian KM,Vaz L, Wagatsuma Y, Breiman RF, Secor WE, Maguire JH, 2006. Loss of leishmanin skin test antigen sensitivity and potency in a longitudinal study of visceral leishmaniasis in Bangladesh. Am J Trop Med Hyg 75:744-748.
14. Mol CJ, Koethe SM, 2006. QuantiFERON TB GOLD: an innovation in tuberculosis screening. AaohnJ 54:245-247.
15. Pai M, Joshi R, Dogra S, Mendiratta DK, Narang P, Dheda K, Kalantri S, 2006. Persistently elevated T cell interferon-gamma responses after treatment for latent tuberculosis infection among health care workers in India: a preliminary report. J Occupat Med Toxicol 1:7.